Siga Technologies earnings release, May 7, 2026

Siga Technologies Inc (SIGA) · Form 8-K, Item 2.02 · Filed · SEC filing

SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update

NEW YORK, May 7, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2026.

“Consistent with our long-term strategy, we expect to deliver more than $35 million of oral and IV TPOXX to a combination of the U.S. Government and an international customer across the second and third quarters of 2026," stated Diem Nguyen, Chief Executive Officer. "Our focus remains on securing new procurement contracts and orders that can drive our business going forward, building upon our long track record as a successful partner to the U.S. and international governments.”

Summary Financial Results

International License Agreement in MENA Region

Key Planned Activities

Capital Management Activity

Conference Call and Webcast

SIGA will host a conference call and webcast to provide a business update today, Thursday, May 7, 2026, at 4:30 P.M. ET.

Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A live webcast of the call will also be available on the Company's website at www.siga.com in the Investor Relations section of the website, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time.

A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID:

1158847. The archived webcast will be available in the Investor Relations section of the

Company's website.

ABOUT SIGA

SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. For more information about SIGA, visit www.siga.com.

Financial statements

Income Statement

Three Months Ended March 31 — Summary Financial Results ($ in millions, except per share amounts)

Three Months Ended March 31 – 2026Three Months Ended March 31 – 2025
Product sales(1)3.55.8
Total revenues(2)6.27
Operating loss(3)-5.3-2.3
Loss before income taxes(3)-4-0.6
Net loss-3.5-0.4
Diluted loss per share-0.05-0.01

Income Statement

Three Months Ended March 31, — CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
RevenuesProduct sales and supportive services3,537,8765,821,247
RevenuesResearch and development2,704,7041,219,568
RevenuesTotal revenues6,242,5807,040,815
Operating expensesCost of sales and supportive services2,940,884157,738
Operating expensesSelling, general and administrative4,673,0145,675,662
Operating expensesResearch and development3,949,8463,462,813
Operating expensesTotal operating expenses11,563,7449,296,213
Operating expensesOperating loss-5,321,164-2,255,398
Operating expensesOther income, net1,277,4801,684,983
Operating expensesLoss before income taxes-4,043,684-570,415
Operating expensesBenefit for income taxes589,432162,192
Operating expensesNet and comprehensive loss-3,454,252-408,223
Operating expensesBasic loss per share-0.05-0.01
Operating expensesDiluted loss per share-0.05-0.01
Operating expensesWeighted average shares outstanding: basic71,649,95771,427,527
Operating expensesWeighted average shares outstanding: diluted71,649,95771,427,527

Balance Sheet

March 31, 2026 — As of

March 31, 2026December 31, 2025
Current assetsCash and cash equivalents145,562,142154,966,414
Current assetsAccounts receivable4,501,6823,263,736
Current assetsInventory56,494,95049,054,873
Current assetsPrepaid expenses and other current assets4,966,9575,571,841
Current assetsTotal current assets211,525,731212,856,864
Current assetsProperty, plant and equipment, net1,673,9731,090,824
Current assetsDeferred tax asset, net5,086,4584,428,519
Current assetsGoodwill898,334898,334
Current assetsOther assets203,362192,893
Current assetsTotal assets219,387,858219,467,434
Current liabilitiesAccounts payable6,306,482824,522
Current liabilitiesAccrued expenses and other current liabilities6,529,8476,520,057
Current liabilitiesDividend payable43,034,458
Current liabilitiesDeferred revenue8,884,12110,240,000
Current liabilitiesIncome tax payable403,517408,000
Current liabilitiesTotal current liabilities65,158,42517,992,579
Current liabilitiesOther liabilities2,607,8312,653,283
Current liabilitiesTotal liabilities67,766,25620,645,862
Stockholders’ equityCommon stock ($.0001 par value, 600,000,000 shares authorized, 71,724,097 and 71,611,302, issued and outstanding at March 31, 2026 and December 31, 2025, respectively)7,1727,161
Stockholders’ equityAdditional paid-in capital242,057,171241,885,214
Stockholders’ equityAccumulated deficit-90,442,741-43,070,803
Stockholders’ equityTotal stockholders’ equity151,621,602198,821,572
Stockholders’ equityTotal liabilities and stockholders’ equity219,387,858219,467,434
Full release

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” within the meaning of the

Private Securities Litigation Reform Act of 1995, as amended, including statements relating to SIGA’s future business development and plans. Forward-looking statements include statements regarding our future financial position, business strategy, budgets, projected costs, plans and objectives of management for future operations, and delivering products to domestic and international customers under procurement contracts, such as the 19C BARDA Contract (the "BARDA Contract"), with the U.S. Biomedical Advanced Research and Development Authority ("BARDA"). The words “may,” “continue,” “estimate,” “intend,” “plan,” “will,” “believe,” “project,” “expect,” “seek,” “anticipate,” “could,” “should,” “target,” “goal,”

“potential” and similar expressions may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Such forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. SIGA’s actual results could differ materially from those anticipated by such forward-looking statements due to a number of factors, some of which are beyond SIGA’s control, including, but not limited to, (i) the risk that SIGA may not complete performance under the BARDA Contract on schedule or in accordance with contractual terms, (ii) the risk that SIGA is not able to enter into new contracts to supply TPOXX® to the U.S. Government, (iii) the risk that the nascent international biodefense market does not develop to a degree that allows SIGA to continue to successfully market TPOXX® internationally, (iv) the risk that potential products, including potential alternative uses or formulations of TPOXX® that appear promising to SIGA or its collaborators, cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (v) the risk that target timing for deliveries of product to customers, and the recognition of related revenues, are delayed or adversely impacted by the actions, or inaction, of contract manufacturing organizations, or other vendors, within the supply chain, or due to coordination activities between the customer and supply chain vendors, (vi) the risk that SIGA or its collaborators will not obtain or maintain appropriate or necessary governmental approvals to market these or other potential products or uses, (vii) the risk that SIGA may not be able to secure or enforce sufficient legal rights in its products, including intellectual property protection, (viii) the risk that any challenge to SIGA’s patent and other property rights, if adversely determined, could affect SIGA’s business and, even if determined favorably, could be costly, (ix) the risk that regulatory requirements applicable to SIGA’s... (truncated) approvals to market these products, (x) the risk that the volatile and competitive nature of the biotechnology industry may hamper SIGA’s efforts to develop or market its products, (xi) the risk that changes in domestic or foreign economic and market conditions may affect SIGA’s ability to advance its research or may affect its products adversely, (xii) the effect of federal, state, and foreign regulation, including drug regulation and international trade regulation, on SIGA’s businesses, (xiii) the impacts of significant recent shifts in trade policies, including the imposition of tariffs, retaliatory tariff measures, and subsequent modifications or suspensions thereof, and market reactions to such policies and resulting trade disputes, (xiv) the risk of disruptions to SIGA’s supply chain for the manufacture of TPOXX®, causing delays in SIGA’s research and development activities, causing delays or the re-allocation of funding in connection with SIGA’s government contracts, or diverting the attention of government staff overseeing SIGA’s government contracts, (xv) risks associated with actions or uncertainties surrounding the debt ceiling, or the changes in the U.S. administration, and (xvi) the risk that the U.S. or foreign governments' responses (including inaction) to national or global economic conditions or infectious diseases, are ineffective and may adversely affect SIGA’s business, as well as the risks and uncertainties included in Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended

December 31, 2025 and SIGA's subsequent filings with the Securities and Exchange Commission. SIGA urges investors and security holders to read those documents free of charge at the SEC's website at http://www.sec.gov. All such forward-looking statements are current only as of the date on which such statements were made. SIGA does not undertake any obligation to update publicly any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

Investor and Media Contact:

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Siga Technologies earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.